ELEVAI Labs Reports Issuance of Patent From U.S. Patent & Trademark Office
The Utility Patent Covers the Formulation for the Company's Flagship Exosome-Based Skincare products
ELEVAI Labs (NASDAQ: ELAB) a medical aesthetic company specializing in physician-dispensed skincare, is pleased to announce that the United States Patent & Trademark Office (USPTO) issued US Patent No. 11,878,038, entitled “Exosome-based Skincare Product” covering the primary formulation for ELEVAI’s exosome-based skin care products.
The ELEVAI exosomesTM used in ELEVAI Labs’ formulations are derived from specially cultured and treated umbilical mesenchymal stem cells to generate a specific profile for the applications desired. ELEVAI’s enfinityTM and empowerTM formulations are both covered by the Patent.
ELEVAI Labs co-founder and CEO, Jordan R. Plews, PhD commented on the announcement, stating:
“We are pleased the USPTO has issued this critical patent, which is the first step towards building ELEVAI’s patent moat in the aesthetics market. The Company will continue to strive to invent or acquire the best and most technically advanced products, which we believe will maintain ELEVAI’s competitive edge in the physician-dispensed skincare market and beyond.”
Elevai Labs Inc. is a paid client of Wealthy VC.
This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.
